

#9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Felgner et al.)	Group Art Unit Unknown
App. No.	:	09/738,046))
Filed	:	December 15, 2000))
For	:	INTRACELLULAR PROTEIN DELIVERY COMPOSITIONS AND METHODS OF USE))
Examiner	:	Unknown))

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410. A duplicate copy of this Statement is enclosed for that purpose.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: _____

Ned A. Israelsen

Registration No. 29,655

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(619) 235-8550

Attach to paper no. 3

SHEET 1 OF 6

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. GTSYS.004A	APPLICATION NO. 09/738,046
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Felgner et al.	
		FILING DATE December 15, 2000	GROUP Unknown
(USE SEVERAL SHEETS IF NECESSARY)			


U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
1.	Bukanov, et al., <u>PD-loop: A complex of duplex DNA with an oligonucleotide</u> ; <i>Proc. Natl. Acad. Sci. USA</i> 95:5516-5520 (1998)
2.	Chemy, et al., <u>DNA unwinding upon strand-displacement binding of a thymine-substituted polyaminide to double-stranded DNA</u> ; <i>Proc. Natl. Acad. Sci. USA</i> 90:1667-1670 (1993)
3.	<u>Conformational and topological requirements of cell-permeable peptide function</u> ; <i>J. Peptide Res.</i> 51:235-243 (1998)
4.	Egholm, et al., <u>Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA</u> ; <i>Nucl. Acids Res.</i> 23(2):217-222 (1995)
5.	<u>Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations</u> ; <i>J. Biol. Chem.</i> 269(4):2550-2561 (1994)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	


FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GTSYS.004A	APPLICATION NO. 09/738,046
		APPLICANT Felgner et al.	
		FILING DATE December 15, 2000	GROUP Unknown



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	6. Felgner, et al., <u>Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure</u> ; <i>Proc. Natl. Acad. Sci. USA</i> 84:7413-7417 (1987)
	7. Felgner, et al., <u>Editorial - Nomenclature for Synthetic Gene Delivery Systems</u> ; <i>Hum. Gene Ther.</i> 8:511-512 (1997)
	8. Glennie and Johnson, <u>Clinical trials of antibody therapy</u> ; <i>Immunol. Today</i> 21:403-410 (2000)
	9. Gregoriadis, et al., <u>Liposome-mediated DNA vaccination</u> ; <i>FEBS Lett.</i> 402:107-110 (1997)
	10. Gregoriadis, et al., <u>Vaccine Entrapment in Liposomes</u> ; <i>Methods</i> 19:156-162 (1999)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GTSYS.004A	APPLICATION NO. 09/738,046
		APPLICANT Felgner et al.	
		FILING DATE December 15, 2000	GROUP Unknown



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	11. Hong, et al., <u>Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery</u> ; <i>FEBS Lett.</i> 400:233-237 (1997)
	12. Leserman and Barbet, <u>Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A</u> ; <i>Nature</i> 288:602-604 (1980)
	13. Liu, et al., <u>Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery</u> ; <i>Nature Biotech.</i> 15:167-173 (1997)
	14. Mhashilkar, et al., <u>Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies</u> ; <i>EMBO J.</i> 14:1542-1551 (1995)
	15. Mhashilkar, et al., <u>Inhibition of Human Immunodeficiency Virus Type 1 Replication In Vitro in Acutely and Persistently Infected Human CD4 Mononuclear Cells Expressing Murine and Humanized Anti-Human Immunodeficiency Virus...</u> ; <i>Hum. Gene Ther.</i> 10:1453-1467 (1999)

EXAMINER	DATE CONSIDERED
----------	-----------------


*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GTSYS.004A	APPLICATION NO. 09/738,046
		APPLICANT Felgner et al.	
		FILING DATE December 15, 2000	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
16.	Mhashilkar, et al., <u>Inhibition of Human Immunodeficiency Virus Type 1 Replication in vitro by a Novel Combination of Anti-Tat single-Chain Intrabodies and NF-KB Antagonists</u> ; <i>J. Virol.</i> 71:6486-6494 (1997)
17.	Reichert, <u>New biopharmaceuticals in the USA: trends in development and marketing approvals 1955-1999</u> ; <i>Trends Biotechnol.</i> 16:370-375 (1998)
18.	Rojas, et al., <u>Controlling Epidermal Growth Factor (EGF)-stimulated Ras Activation in Intact Cells by a Cell-permeable peptide Mimicking Phosphorylated EGF Receptor</u> ; <i>J. Biol. Chem.</i> 271:27456-27461 (1996)
19.	Rojas, et al., <u>Genetic engineering of proteins with cell membrane permeability</u> ; <i>Nature Biotechnol.</i> 16:370-375 (1998)
20.	Schwarze, et al., <u>In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse</u> ; <i>Science</i> 285:1569-1572 (1999)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GTSYS.004A	APPLICATION NO. 09/738,046
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Felgner et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE December 15, 2000	GROUP Unknown




EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	21. Schwarze, et al., <u>Protein transduction: unrestricted delivery into all cells?</u> ; <i>Trends Cell Biol.</i> 10:290-295 (2000)
	22. Tseng, et al., <u>Transfection by Cationic Liposomes Using Simultaneous Single Cell Measurements of Plasmid Delivery and Transgene Expression</u> ; <i>J. Biol. Chem.</i> 272:25641-25647 (1997)
	23. Zelphati, et al., <u>Gene Chemistry: Functionally and Conformationally Intact Fluorescent Plasmid DNA</u> ; <i>Hum. Gene Ther.</i> 10:15-24 (1999)
	24. Zelphati, et al., <u>Intracellular Distribution and Mechanism of Delivery of Oligonucleotides Mediated by Cationic Lipids</u> ; <i>Pharm. Res.</i> 13:1367-1372 (1996)
	25. Zelphati, et al., <u>Mechanism of oligonucleotide release from cationic liposomes</u> ; <i>Proc. Natl. Acad. Sci. USA</i> 93:11493-11498 (1996)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GTSYS.004A	APPLICATION NO. 09/738,046
		APPLICANT Felgner et al.	
		FILING DATE December 15, 2000	GROUP Unknown



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
26.	Zelphati, et al., PNA-Dependent Gene Chemistry: Stable Coupling of Peptides and Oligonucleotides to Plasmid DNA ; BioTechniques 28:304-310 (2000)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.